A carregar...
Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR
Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR) that has been approved for the treatment of metastatic non-small cell lung cancer (NSCLC) positive for the secondary T790M mutation of EGFR. In a preclinical study, it also showed efficac...
Na minha lista:
| Publicado no: | ESMO Open |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMJ Publishing Group
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5559906/ https://ncbi.nlm.nih.gov/pubmed/28848674 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2016-000104 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|